NewsHive
CONTACT USANALYST PORTAL →
crossBACKGROUND

mRNA cancer vaccine succeeded in Phase 3 melanoma trial, Moderna and Merck say

BACKGROUND
1 SIGNALFIRST DETECTED 19 August 2026
Narrative synthesis pending — 1 signal collected.
How the story developed
19 Aug
Other feeds and industry voices
20 Aug
The mRNA-based vaccine—individually tailored to target a patient’s unique cancer mutations—was effective in a late-stage clinical trial of patients with one of the deadliest forms of skin cancer.

The mRNA-based vaccine—individually tailored to target a patient’s unique cancer mutations—was effective in a late-stage clinical trial of patients with one of the deadliest forms

OPINION · WHAT · Ars TechnicaOPEN STORY
19 Aug
Moderna reports first positive Phase 3 for mRNA neoantigen therapy in melanoma

<a href="https://news.ycombinator.com/item?id=49361395">Comments</a>

REPORT · WHAT · Hacker News Best (RSS)OPEN STORY
19 Aug
Moderna stock, $MRNA , surges over +110% after announcing the first ever positive Phase 3 results for a personalized cancer vaccine.

<table> <tr><td> <a href="https://www.reddit.com/r/singularity/comments/1vso1mh/moderna_stock_mrna_surges_over_110_after/"> <img alt="Moderna stock, $MRNA , surges over +110%

OPINION · WHAT · singularityOPEN STORY
Sources
Ars Technica

NewsHive monitors these sources continuously. All signal titles above link to the original reporting.

Intelligence by NewsHive. Need help navigating what this means for your business? Contact GeekyBee →